How do senolytics work, which has the best evidence, and what's a reasonable protocol?

What senolytics actually are

Evidence tier: 3 — preclinical evidence is strong; human RCT evidence is emerging but limited.

Senolytics are drugs that selectively kill senescent cells — cells that have stopped dividing but resist apoptosis, accumulate in aging tissues, and secrete inflammatory factors (the "senescence-associated secretory phenotype" or SASP). Senescent cell accumulation is one of the more rigorously characterized hallmarks of aging, with strong evidence from genetic mouse models that clearing them improves healthspan.

The senolytic field has three reasonably-evidenced interventions in 2026:

• Fisetin: a flavonoid found in strawberries and other plants; most-evidenced natural senolytic with Phase 2 trials underway
• Dasatinib + Quercetin (D+Q): a combination of an FDA-approved leukemia drug (dasatinib) with a flavonoid (quercetin); the most-evidenced small-molecule senolytic with multiple Phase 2 readouts
• FOXO4-DRI: a peptide-class senolytic with strong mouse evidence; see the FOXO4-DRI article

This article covers Fisetin and D+Q — the non-peptide senolytics most discussed in protocols beyond FOXO4-DRI.

The honest framing: senolytics are one of the most evidence-anchored longevity interventions, with multiple Phase 2 trials reporting real effects on age-related disease biomarkers. The catch: most published trials are short-term (single-month protocols) and don't yet establish long-term healthspan improvement. The mechanism is well-validated; the clinical translation is mid-stage.

The mechanism

Evidence tier: 2 — well-characterized.

Senescent cells share several biochemical features that senolytics exploit:

• Up-regulated anti-apoptotic pathways: senescent cells survive by elevating BCL-2 family proteins, particularly BCL-XL and BCL-W. They depend on these for survival.
• Increased reliance on tyrosine kinase signaling: certain tyrosine kinase pathways are elevated in senescent cells, making them vulnerable to specific kinase inhibitors
• Mitochondrial dysfunction with oxidative stress: makes them susceptible to additional oxidative challenge
• SASP cytokine production: drives the inflammatory damage to surrounding tissue but also represents a vulnerability

The senolytic strategy is to target these vulnerabilities selectively, killing senescent cells while leaving healthy cells intact. Different senolytics target different vulnerabilities:

• Fisetin: PI3K/AKT pathway modulation + BCL-2 family inhibition + ROS effects
• Dasatinib: broad tyrosine kinase inhibition (BCR-ABL, SRC, KIT family) — kills senescent cells dependent on these pathways
• Quercetin: PI3K/AKT inhibition + BCL-XL inhibition — complementary to dasatinib
• FOXO4-DRI: disrupts FOXO4-p53 interaction that senescent cells require for survival

The combination logic of D+Q: dasatinib kills senescent fat cells and some other types; quercetin kills senescent endothelial cells. Together they cover more senescent cell types than either alone.

Fisetin — the natural senolytic

Evidence tier: 3 — strong preclinical evidence; Phase 2 trials underway.

Mechanism: Fisetin is a polyphenol that selectively kills senescent cells through multiple vulnerabilities (PI3K/AKT, BCL-2, oxidative stress). It's relatively unique among natural flavonoids in having demonstrated senolytic activity at achievable serum concentrations.

Preclinical evidence: Yousefzadeh et al 2018 (Aging Cell) — the seminal Fisetin senolytic paper. Fisetin extended healthspan in old mice when administered orally. Multiple subsequent animal studies have replicated the core finding.

Clinical trial status: Phase 2 trials are underway through 2026 at Mayo Clinic and other institutions, examining Fisetin's effects on age-related disease biomarkers, frailty, and physical function in elderly subjects. Readouts are awaited.

Available evidence: real but limited. Animal studies are consistent; human trials are pending. Early Phase 2 readouts suggest favorable safety profile and biomarker effects on inflammatory cytokines.

Practical protocol: - 20 mg/kg orally, 2 consecutive days per month - (For 70 kg adult: ~1,400 mg/day × 2 days) - Cycle monthly or quarterly - Take with fat (improves bioavailability) - Cost: $30-60/month at pharmaceutical-grade supplement quality

Important framing: Fisetin is sold widely as a supplement at lower doses. The senolytic dose (20 mg/kg pulses) is substantially higher than typical supplement dosing (typically 100-500 mg). Most "Fisetin supplement" purchases at standard dose don't achieve senolytic concentrations.

Dasatinib + Quercetin (D+Q) — the small-molecule combination

Evidence tier: 3 — strongest senolytic evidence base; multiple Phase 2 readouts.

Mechanism: Dasatinib is an FDA-approved tyrosine kinase inhibitor for chronic myeloid leukemia (Sprycel). At low pulse-dose, it selectively kills senescent cells dependent on TK signaling. Quercetin is a flavonoid that complements dasatinib by killing senescent endothelial cells via different pathways.

Preclinical evidence: extensive. Zhu et al 2015 (Aging Cell) was the seminal paper. Multiple subsequent studies have shown D+Q clears senescent cells in mouse tissues and improves age-related dysfunction.

Clinical trial evidence: - Justice et al 2019: D+Q in idiopathic pulmonary fibrosis patients showed improvement in physical function - Hickson et al 2019: D+Q in diabetic kidney disease patients reduced senescent cell markers in adipose tissue - Multiple ongoing Phase 2 trials in IPF, diabetic kidney disease, frailty, and Alzheimer's

The clinical evidence base for D+Q is the strongest among senolytics in 2026. The Phase 2 readouts are real and biomedically meaningful.

Practical protocol: - Dasatinib 100 mg + Quercetin 1,000 mg per day, 2-3 consecutive days - Cycle monthly or quarterly - Take with food - Cost: dasatinib (Rx required) $300-800 per cycle; quercetin $20-40 per cycle - Requires prescription for dasatinib

Important framing: Dasatinib is a prescription-only oncology drug with a meaningful side-effect profile in its FDA-approved chronic-dosing leukemia context. At pulse-dose senolytic use (2-3 days per cycle), the side-effect profile is much milder than chronic dosing, but it remains a real drug with real considerations — pleural effusion risk, bleeding risk (avoid with anticoagulants), drug-drug interactions (CYP3A4 substrates), and others. Use requires physician oversight.

Fisetin vs D+Q — practical comparison

Evidence tier: 3 — informed comparison.

Strength of evidence: - D+Q: stronger published clinical evidence base; multiple Phase 2 readouts - Fisetin: strong preclinical; Phase 2 trials underway

Senescent cell types cleared: - D+Q: broader spectrum (different cell types via different mechanisms) - Fisetin: more focused; may need to combine with other interventions for full effect

Safety profile: - Fisetin: very clean; supplement-grade safety profile - D+Q: cleaner than expected for an oncology drug at pulse-dose, but real considerations apply

Access: - Fisetin: OTC supplement - D+Q: dasatinib requires prescription; quercetin is OTC

Cost: - Fisetin: $30-60/month - D+Q: $320-840 per cycle (every 1-3 months)

Decision framework: - Conservative starter / supplement-only: Fisetin - Stronger-evidence-priority: D+Q with physician oversight - Both possible: alternate Fisetin (months 1, 3, 5) and D+Q (months 2, 4, 6) if physician supportive

For most users new to senolytics, Fisetin is the reasonable starting point. Adding D+Q is a step further that requires physician engagement and is worth doing if longevity protocol is mature and prescriber relationship supports it.

Where senolytics fit in a longevity stack

Evidence tier: 4 — practitioner positioning.

Foundation layer: lifestyle (Mediterranean diet, exercise, sleep, body composition, cardiovascular risk reduction). Senolytics don't substitute for foundation.

Strong-evidence pharmaceutical layer: Rapamycin (mTOR), Metformin (AMPK). Senolytics complement these via different mechanism.

Senolytic layer: Fisetin and/or D+Q at quarterly cycles. Senescent cell clearance is mechanistically non-overlapping with mTOR/AMPK pathways.

NAD+ precursor layer: NR or NMN at 500-1,000 mg/day. Different mechanism from senolytics.

Peptide layer: FOXO4-DRI for users seeking peptide-class senolytic. GHK-Cu for skin/tissue. BPC-157 for tissue repair contexts.

Weaker-evidence layer: Epitalon and other Russian peptide bioregulators if appetite for weaker-evidence interventions.

The senolytic layer has stronger evidence than NAD+ precursors or peptide bioregulators in 2026, though weaker than rapamycin/metformin. Reasonable middle-tier longevity intervention.

Monitoring + safety

Evidence tier: 3 — well-characterized for the established interventions.

Fisetin: - Generally clean safety; mild GI upset occasional - Theoretical drug interactions (Fisetin inhibits CYP3A4); check medication list - Standard blood work at baseline + annually

D+Q: - Dasatinib: requires prescription + physician oversight - Pleural effusion risk (rare at pulse-dose, real at chronic dose) - Bleeding risk — avoid with anticoagulants or active bleeding - CYP3A4 interactions extensive — check medication list including supplements - Cardiac monitoring (QT prolongation) for high-risk users - Baseline + post-cycle CBC, CMP

General senolytic monitoring: - Inflammatory markers (CRP, IL-6) — should decrease over months on regimen - Physical function markers if available - Body composition tracking - Sleep quality / energy / recovery (subjective)

Contraindications to senolytic intervention: - Active malignancy without oncology coordination - Active infection - Pregnancy/nursing - Severe bleeding disorders (D+Q specifically) - Active pleural disease (D+Q specifically) - Drug-interaction overload (multiple CYP3A4-affected medications)

When senolytics aren't the right intervention

Evidence tier: 4 — clinical judgment.

• Foundation lifestyle not addressed: poor sleep, poor diet, sedentary lifestyle — senolytics won't compensate
• Age <40 without specific senescence-driven condition: senescent cell burden is lower; intervention rationale is weaker
• Active malignancy: senolytic mechanism could theoretically affect tumor biology in unpredictable ways; oncology guidance required
• Active pregnancy or fertility intervention: contraindicated
• Active acute illness: defer until recovery
• Complex medication regimens with CYP3A4 substrates: drug-interaction complexity
• Unable to engage prescriber for dasatinib portion: stick with Fisetin alone

A reasonable starter protocol

Evidence tier: 4 — practitioner guidance.

For a 50-year-old with foundation lifestyle in place, addressing longevity in a systematic way:

Phase 1 (months 1-3): - Foundation lifestyle continued - Fisetin 20 mg/kg orally × 2 consecutive days, monthly - Standard blood work at baseline

Phase 2 (months 4-6): - If responder + prescriber supportive: add D+Q quarterly - Dasatinib 100 mg + Quercetin 1,000 mg × 2-3 consecutive days - Continue Fisetin monthly - Inflammatory markers + physical function + body comp tracking

Phase 3 (months 7+): - Maintain the protocol if responder - Alternate Fisetin (months 1, 3, 5) and D+Q (months 2, 4, 6) if simplification preferred - Annual blood work

Don't escalate beyond quarterly D+Q cycles or monthly Fisetin — the senolytic mechanism is pulse-target, not continuous. More frequent dosing doesn't improve effect and increases adverse-event risk.

Limitations

This is not medical advice. Real limits:

• Foundation lifestyle first — senolytics amplify lifestyle, don't substitute
• D+Q requires physician oversight — dasatinib is prescription oncology drug
• Avoid in active malignancy without oncology coordination
• Don't use during pregnancy/nursing without specialist input
• Check drug interactions — both Fisetin and Dasatinib affect CYP3A4
• Pulse-dosing, not continuous — senolytic mechanism is intermittent
• Monitor inflammatory markers — CRP, IL-6 should trend down over months
• Cost matters — D+Q is meaningfully more expensive than Fisetin
• Stop if persistent adverse effects emerge

The bottom line

Senolytics are one of the better-evidenced longevity interventions available in 2026, with Fisetin and Dasatinib + Quercetin both demonstrating real biomarker effects in Phase 2 human trials. The mechanism — selective killing of senescent cells — is well-validated; the clinical translation is mid-stage with positive Phase 2 readouts.

Fisetin is the reasonable starting point: OTC supplement-grade access, clean safety profile, monthly pulse-dose at 20 mg/kg. D+Q is the stronger-evidence option but requires prescriber engagement and has real drug-class considerations.

Senolytics complement rather than substitute for foundation lifestyle interventions, rapamycin/metformin, and NAD+ precursors. The pulse-dosing strategy (quarterly cycles, not continuous) reflects the underlying biology and is well-tolerated.

For users building a longevity stack beyond FOXO4-DRI, Fisetin and D+Q are the most-evidenced additions.

What we'll be tracking

• Mayo Clinic and other Phase 2 Fisetin trial readouts
• Phase 3 trial readouts for D+Q in IPF, diabetic kidney disease, frailty
• Combination senolytic protocols (Fisetin + D+Q + FOXO4-DRI)
• Long-term healthspan and mortality data from chronic senolytic users
• New senolytic mechanisms entering Phase 1/2 development

For ongoing context, see the Longevity pillar, the FOXO4-DRI senolytic peptide article, the Epitalon tripeptide review, and the NAD+ peptides and longevity stack.

References

• Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. 2018. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. PMID 30279143
• Zhu Y, Tchkonia T, Pirtskhalava T, et al. 2015. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. PMID 25754370
• Justice JN, Nambiar AM, Tchkonia T, et al. 2019. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. PMID 30616998
• Hickson LJ, Langhi Prata LGP, Bobart SA, et al. 2019. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. PMID 31542391
• Kirkland JL, Tchkonia T. 2017. Cellular senescence: a translational perspective. EBioMedicine. PMID 28049584